Deutsche Bank AG Has $1.10 Million Stake in STAAR Surgical (NASDAQ:STAA)

Deutsche Bank AG boosted its position in shares of STAAR Surgical (NASDAQ:STAA) by 6.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 45,193 shares of the medical instruments supplier’s stock after acquiring an additional 2,932 shares during the quarter. Deutsche Bank AG owned 0.09% of STAAR Surgical worth $1,098,000 at the end of the most recent reporting period.

Other large investors have also recently added to or reduced their stakes in the company. KLP Kapitalforvaltning AS acquired a new position in STAAR Surgical in the 4th quarter valued at about $180,000. Bridgefront Capital LLC boosted its holdings in shares of STAAR Surgical by 27.2% during the fourth quarter. Bridgefront Capital LLC now owns 10,792 shares of the medical instruments supplier’s stock worth $262,000 after acquiring an additional 2,306 shares during the period. Quantbot Technologies LP acquired a new position in shares of STAAR Surgical in the fourth quarter valued at approximately $278,000. Y Intercept Hong Kong Ltd bought a new position in shares of STAAR Surgical during the fourth quarter worth approximately $292,000. Finally, Counterpoint Mutual Funds LLC bought a new position in shares of STAAR Surgical during the fourth quarter worth approximately $298,000. Institutional investors and hedge funds own 96.70% of the company’s stock.

Insider Transactions at STAAR Surgical

In other news, major shareholder Broadwood Partners, L.P. acquired 8,200 shares of STAAR Surgical stock in a transaction on Wednesday, April 9th. The stock was acquired at an average cost of $15.08 per share, with a total value of $123,656.00. Following the completion of the acquisition, the insider now owns 13,518,591 shares in the company, valued at approximately $203,860,352.28. This trade represents a 0.06% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders bought a total of 1,446,433 shares of company stock worth $23,957,807 in the last quarter. 1.00% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Stifel Nicolaus reduced their price target on STAAR Surgical from $38.00 to $20.00 and set a “buy” rating for the company in a research note on Wednesday, February 12th. Needham & Company LLC reissued a “hold” rating on shares of STAAR Surgical in a research report on Wednesday, May 21st. Piper Sandler lowered their price target on shares of STAAR Surgical from $40.00 to $16.00 and set a “neutral” rating on the stock in a research report on Wednesday, February 12th. Wells Fargo & Company initiated coverage on shares of STAAR Surgical in a research note on Monday, April 21st. They issued an “equal weight” rating and a $17.00 price objective for the company. Finally, Stephens reissued an “equal weight” rating and issued a $17.00 price objective on shares of STAAR Surgical in a report on Tuesday, March 18th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $24.63.

STAAR Surgical Stock Performance

Shares of STAAR Surgical stock opened at $18.68 on Monday. The stock has a market capitalization of $925.15 million, a PE ratio of -45.56 and a beta of 0.65. STAAR Surgical has a 52 week low of $13.50 and a 52 week high of $49.86. The stock has a 50 day moving average price of $17.72 and a two-hundred day moving average price of $21.08.

STAAR Surgical declared that its board has authorized a stock repurchase program on Friday, May 16th that permits the company to buyback $30.00 million in shares. This buyback authorization permits the medical instruments supplier to reacquire up to 3.2% of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board believes its shares are undervalued.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.